These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Induction of abortion during the second and third trimester of pregnancy with sulprostone (author's transl)].
    Author: Heinzl S, Winkler C.
    Journal: Geburtshilfe Frauenheilkd; 1981 Mar; 41(3):231-6. PubMed ID: 7215768.
    Abstract:
    Report on 114 terminations of pregnancy during the second and third trimester of pregnancy with a new prostaglandin E2 derivative "Sulprostone". In 84 cases legal therapeutic abortions were induced. In 30 women an abnormal pregnancy was terminated. "Sulprostone: is a prostaglandin with selective activity in the uterus. It can be administered parenterally or locally. 48 women received intravenous sulprostone, 35 patients had extraamniotic injections and 31 patients had extra-amniotic injections following an intramuscular injection for priming of the cervix the night before. In 103 women the pregnancy was terminated within the first 24 hours after the administration of sulprostone (90.3%). 8 patients (7.0 %) had a cervical dilatation over 2 cm. In 3 women no effect was noted. In 1 patient the prostaglandin application was stopped because of severe vomiting. The mean administration abortion interval was 12 hours and 54 minutes following extra amniotic application and 10 hours and 30 minutes with extra amniotic application and following intramuscular priming. In 5 patients the abortion was completed after the priming administration. More than 90% of the patient's required analgesia. There were 32.4% side effects of mild character. The results and the methods are described and compared to other methods. A report is presented on 114 terminations of pregnancy during the second and third trimesters of pregnancy with a new (PGE) prostaglandin E2 derivative Sulprostone. In 84 cases, legal therapeutic abortions were induced. In 30 women an abnormal pregnancy was terminated. Sulprostone is a PG with selective activity in the uterus. It can be administered parenterally or locally. 48 women received intravenous sulprostone, 35 patients had extraamniotic injections and 31 patients had extraamniotic injections following an intramuscular injection for priming of the cervix the night before. In 103 women, the pregnancy was terminated within the first 24 hours after the administration of sulprostone (90.3%). 8 patients (7.0%) had a cervical dilatation over 2 cm. In 3 women no effect was noted. In 1 patient, the PG application was stopped because of severe vomiting. The mean administration abortion interval was 12 hours with intravenous infusion of sulprostone, 12 hours and 54 minutes following extraamniotic application and 10 hours and 30 minutes with extraamniotic administration following intramuscular priming. In 5 patients the abortion was completed after the priming administration. More than 90% of the patients required analgesia. 32.4% displayed side effects, all of mild character. The results and the methods are described and compared to other methods. (Author's modified)
    [Abstract] [Full Text] [Related] [New Search]